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Abstract: Pickering-stabilized antibubbles were used as a new method to encapsulate Lactobacillus casei.
Antibubbles consist of one or more liquid droplets within a shell of gas. The antibubbles were
prepared from a water-in-oil-in-water (W/O/W) emulsion stabilized by silica particles, which was then
freeze-dried to remove the water and oil phases, before being subsequently reconstituted in water.
Different oil phases and aqueous phase compositions were tested for their effect on the survival of
the bacteria. The survival of L. casei after encapsulation using decane was 29.8 ± 2.1% in antibubbles
containing 10% (w/v) maltodextrin plus 8% (w/v) sucrose, which is comparable to the survival when
bacteria were freeze-dried without being encapsulated. Encapsulation within antibubbles led to a 10
to 30 times higher survival of L. casei at pH 2 in comparison with unencapsulated bacteria. This study
shows that probiotics can be encapsulated within a shell of gas through the use of antibubbles and
that this protects probiotics against a low pH.
Keywords: Lactobacillus casei; antibubble; encapsulation; probiotics
1. Introduction
Probiotics are live microorganisms, which, when administered in adequate amounts, confer a
health benefit on the host. They can provide health benefits such as an enhancement of the immune
system, prevention of allergy and intestinal infection, and can display an anticholesterolemic and
anticarcinogenic activity [1]. Though different kinds of genera and species of microorganisms are
considered to be probiotics, several strains from the genera Lactobacillus and Bifidobacterium constitute
the main probiotic bacteria in use nowadays [2]. To exert therapeutic effects on the host, it is necessary
that biologically active probiotic bacteria reach the intestine in a viable way and in sufficient numbers.
However, most probiotics are highly sensitive to the harsh conditions in some foods and in the
acidic-bile conditions of the gastrointestinal tract [3]. Therefore, the effective application of probiotics
is a crucial challenge in the food and pharmaceutical industry. This has encouraged researchers to look
for effective strategies, such as microencapsulation, to preserve cell viability and probiotic functions [4].
Microencapsulation is a technology in which bacteria are entrapped in the core of materials within
a shell designated as encapsulating or wall material. Microencapsulation provides a physical barrier
against environmental stress [5] and therefore minimizes the loss of viability of probiotics during
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processing, storage and digestion, ensuring a targeted delivery in the gut [6,7]. Microparticles’ sizes
vary between a few microns to 1 mm. Various methods of encapsulation, such as emulsification,
extrusion, spray drying, freeze-drying and coacervation, have been developed [8]. In spite of a large
number of studies on encapsulation, this technology is still under active investigation and has attracted
broad interest from the pharmaceutical and food industry for different applications.
Out of the many materials that have already been used to encapsulate actives, there is one
shell component that has hitherto been overlooked: gas. Antibubbles (also referred to as inverse
bubbles) consist of one or more liquid droplets within a gas shell. The antibubbles can be used to
encapsulate substances by loading these droplets with the substance to be encapsulated. The shell of
gas that surrounds the droplets provides an excellent barrier to nonvolatile substances. This barrier
disappears almost instantaneously when the gas shell ruptures, e.g., in response to an external
trigger [9]. Antibubbles thus have the potential to be used as encapsulates with good barrier properties
and the possibility of a fast and complete triggered release. This would make antibubbles an ideal
type of encapsulation, and hence antibubbles are attracting interest [10]. However, due to their short
lifetime, antibubbles have not yet been applied. Recently, this limitation was solved by using a so-called
Pickering stabilization to produce stable micro-antibubbles [11,12]. Pickering stabilization refers to the
stabilization of interfaces by adsorbed solid particles instead of surfactants [13,14]. Pickering-stabilized
micro-antibubbles can be produced by first making a particle-stabilized water-in-oil-in-water (W/O/W)
emulsion, in which the two water phases contain a solute that becomes glassy upon drying, and in
which the oil phase is volatile. The next step is to remove the water and oil by freeze-drying the
W/O/W emulsion. Antibubbles are obtained when this freeze-dried material is reconstituted in
water [11]. Hydrophobized silica particles are one of the most commonly applied materials in the
formulation of Pickering emulsions [13]. These hydrophobized silica particles are allowed in the use of
food, feed, cosmetics and oral pharmaceuticals [15].
To date, neither the encapsulation of probiotics in antibubbles nor the use of antibubbles for
controlled release purposes has been reported. This work provides an initial check on the potential of
antibubbles for the encapsulation of L. casei ATCC 393 as a probiotic model organism. We studied the
survival of the bacteria during encapsulation, the encapsulation efficiency and the protective effect
of the encapsulation against a low pH, and we determined if bile salts can trigger the release of the
encapsulated bacteria.
2. Materials and Methods
2.1. Materials
Maltodextrin (DE 13.0–17.0) was obtained from Sigma–Aldrich (Ltd, Lincoln, NE, USA). Sucrose
was purchased from a local grocery store. Lactobacilli de Man Rogosa Sharpe (MRS) broth and
agar were obtained from Oxoid (Ltd, Wiltshire, England) and Becton, Dickinson and Company
(East Rutherford, NJ, USA), respectively. Aerosil R972-hydrophobized fumed silica particles were
supplied by Evonik. Decane was purchased from TCI (Gillman, Australia). Cyclohexane was obtained
from Sigma–Aldrich (Ltd, Lincoln, NE, USA). All water used in the experiments was Milli Q grade.
2.2. Bacteria, Culture Conditions and Preparation of Cell Concentrate
L. casei ATCC 393 was a kind gift from Prof. Dr. Jan Kok (Molecular Genetics, University of
Groningen). Single colonies of L. casei were obtained after 48 h of incubation at 37 ◦C on MRS-agar.
A single colony was inoculated into a 100 mL fresh sterile MRS broth and incubated overnight at 37 ◦C
in a shaking incubator at 200 rpm. A volume of 4 mL of this liquid culture was mixed with 1 mL of
sterilized 80% glycerol solution, stored at −80 ◦C and used as stocks. Before encapsulation, single
colonies grown on MRS-agar (inoculated from the −80 ◦C stocks) were cultured in 200 mL MRS broth
for 20 h at 37 ◦C in a shaking incubator at 200 rpm. Bacteria were harvested by centrifugation at 8000× g
for 12 min at 10 ◦C. The supernatant was removed, and the pellet was weighed so that the bacterial
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concentration could be calculated. The pellet generally contained about 5 × 109 Colony-Forming Units
per mL (CFU/mL).
2.3. Preparation of Antibubbles
Figure 1 shows the process (consisting of three steps: producing a double emulsion (Figure 1A),
freeze-drying the double emulsion (Figure 1B) and reconstituting the resulting dried material in an
aqueous phase (Figure 1C)) used to encapsulate probiotics in antibubbles. The pellet obtained by
centrifuging the bacterial culture was added to a maltodextrin solution (10% w/v) with or without
sucrose (8% w/v) to prepare a suspension containing 4 × 108 CFU/mL probiotic bacteria. To prepare
a particle-stabilized water-in-oil (W/O) emulsion, 5 mL of the suspension was added to 15 mL of oil
containing 2.5% hydrophobized fumed silica particles and emulsified using a Turrax (IKA-Werke
GmbH & Co. KG, Staufen im Breisgau, Germany) at 10,000 rpm for 30 s. The aqueous phase of the
W/O emulsion is referred to as the ‘inner water phase’. Four different volatile oils were tested for
their ability to form antibubble-encapsulated probiotics: ethyl acetate, ethyl butyrate, cyclohexane
and decane. The obtained W/O emulsion was subsequently emulsified at a concentration of 25% in
a solution of maltodextrin (10% w/v) containing 0.5% hydrophobized fumed silica using a Turrax
mixer at 4000 rpm for 30 s to make a particle-stabilized water-in-oil-in-water emulsion. Before use,
all the media and solutions were sterilized at 121 ◦C for 15 min in an autoclave. Dispersing the silica
particles in the oil or water phase was done using an ultrasound probe (Branson Ultrasonic Sonifier
S-250, Danbury, CT, USA). Particle-stabilized W/O/W emulsions were flash-frozen in liquid nitrogen,
freeze-dried for 48 h using a vacuum freeze-dryer (Christ, Alpha 2–4 LD, Hagen, Germany) at a chamber
pressure of 0.1 mbar. The powder obtained after freeze-drying (which we will refer to as ‘antibubble
powder’) could be reconstituted in an aqueous phase, leading to the formation of a suspension of
antibubbles. It is important to note that freeze-drying is therefore part of the process to encapsulate
bacteria inside antibubbles. For comparison purposes, we also produced freeze-dried formulations
containing unencapsulated bacteria. In that case, maltodextrin solutions (10% w/v) with or without
sucrose (8% w/v) containing 4 × 108 CFU/mL probiotic bacteria were flash-frozen in liquid nitrogen
and freeze-dried in the same way as the W/O/W emulsions that were used to produce encapsulated
bacteria. We refer to the dried material obtained this way as ‘unencapsulated bacteria powder’.
Figure 1. Schematic representation of the structure and stepwise production of antibubble-encapsulated
bacteria. (A): an oil droplet containing emulsified water droplets containing bacteria, as produced by
two consecutive emulsification steps. This water-in-oil-in-water (W/O/W) emulsion is stabilized by
silica particles adsorbed at the interfaces. (B): antibubble powder structure, obtained after freeze-drying
the W/O/W emulsion. This removes the volatile oil from the W/O/W emulsion and converts the inner
and outer aqueous phases of the W/O/W emulsion into a dry carbohydrate matrix. (C): antibubble
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structure obtained after reconstituting the antibubble powder in an aqueous phase. This leads to the
rehydration of both the inner and outer carbohydrate matrices of the antibubble powder. The resulting
structure consists of bubbles that contain droplets, with the droplets containing bacteria. One such
bubble is shown. The blue dashes in the middle image indicate that these phases have become porous
solid matrices due to freeze-drying. The arrows below the figure indicate the processing step that
converts one structure into the other.
2.4. Survival of L. casei during the Encapsulation Process
To evaluate the survival of L. casei during encapsulation, 0.1 g of the antibubble powder obtained
after freeze-drying was dissolved in 20 mL of the same solution used previously as the outer water
phase to produce the antibubble type under investigation. This was done to match the osmotic pressure
of the inner droplets of the antibubbles, in order to prevent the swelling or shrinkage of these inner
droplets. Tests were performed directly after freeze-drying. To allow the counting of the number
of viable bacteria, the encapsulated bacteria were released from the antibubbles by emulsifying the
antibubble suspension using a Turrax mixer at 10,000 rpm for 30 s. Using unencapsulated bacteria,
we checked that this emulsification treatment did not significantly affect the viability of the bacteria.
The number of viable bacteria was determined via spread-plating serial 10-fold dilutions of destroyed
antibubbles on MRS agar. After incubation at 37 ◦C for 48 h, the number of colonies was used to
determine the viability of the L. casei bacteria. For the unencapsulated bacteria, 0.01 g of unencapsulated
bacteria powder was added to 20 mL of the same outer water phase. In such cases, only 0.01 g of
powder was used because, for these powders, the amount of CFU added was ten times higher than for
the formulations containing encapsulated bacteria. The survival of bacteria during encapsulation and
freeze-drying was calculated as the ratio between the measured number of CFU and the number of
CFU added to the formulation.
To evaluate the entrapment efficiency, 0.1 g of the antibubble powder was suspended in 20 mL
of the same solution used previously as the outer water phase to produce this antibubble type.
The suspension was left to stand for 10 min to allow the antibubbles to rise to the top of the suspension.
One mL of the supernatant below this antibubble foam was taken using a sterile syringe and cultured
on MRS agar at 37 ◦C for 48 h to count the number of bacteria that were not entrapped inside the
antibubbles, i.e., that were unencapsulated.
The following equation was used to evaluate the entrapment efficiency:





where X is the total number of viable bacteria and Y is the number of viable unencapsulated bacteria in
the antibubble powder.
2.5. Triggered Release along the Digestive Tract
To have a first indication of whether the release of the bacteria along the digestive tract could be
triggered, 10% of a 5% bile extract (Sigma B3883) solution was added to an antibubble suspension,
and the condition of the antibubbles was observed microscopically.
2.6. Survival of Unencapsulated and Encapsulated L. casei at Low pH
To evaluate the protective effect of the encapsulation against a low pH, 0.1 g of the antibubble
powder (directly after freeze-drying) was added to 20 mL of the same solution used previously as
the outer water phase to produce this antibubble type and was adjusted to pH 2 with 6 M HCl.
The suspensions were incubated at room temperature for 1 h. After this, the suspension was
neutralized by adding 200 mM phosphate buffer pH 6.9. The encapsulated bacteria were released from
the antibubbles by emulsifying the suspension with a Turrax mixer at 10,000 rpm for 30 s and were
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serially diluted and cultured on MRS agar at 37 ◦C for 48 h to determine the number of viable bacteria.
For the unencapsulated bacteria, 0.01 g of unencapsulated bacteria powder was used.
2.7. Statistical Analysis
All experiments were carried out in triplicate, and the values were expressed as the mean
value ± standard deviation. The significance of the differences was determined using a Student’s t-test
(α = 0.05) in Microsoft Excel.
3. Results and Discussion
3.1. Antibubble Production
Antibubble-encapsulated bacteria were obtained by producing a W/O/W emulsion stabilized
by hydrophobized silica particles and with L. casei incorporated in the inner water phase of the
W/O/W emulsion. Both the water and the volatile oil were subsequently removed by freeze-drying,
giving a powder that, upon reconstitution in water, formed antibubbles containing probiotic bacteria.
Preliminary experiments to determine the appropriate volatile oil, using ethyl acetate, ethyl
butyrate, cyclohexane and decane, revealed that the use of ethyl acetate or ethyl butyrate did not
allow the formation of Pickering-stabilized W/O/W emulsions. The relatively high polarity of these
compounds probably requires particles with a different hydrophobicity to stabilize the interface
between the oil and water phases [16]. On the other hand, cyclohexane and decane allowed for the
preparation of Pickering-stabilized W/O/W emulsions and were thus selected to produce four types
of antibubbles, which were obtained by combining cyclohexane or decane with maltodextrin, either
alone or with additional sucrose, in the inner and outer water phase (Table 1).
Table 1. Compositions that allowed for the successful production of antibubbles. C: cyclohexane;
D: decane; M: maltodextrin; S: sucrose.








DMS 10% Maltodextrin + 8% Sucrose
The structure of the antibubbles in a stepwise production using decane and 10% maltodextrin +
8% sucrose, visualized by phase-contrast microscopical imaging, is shown in Figure 2. Images were
also obtained for the other formulations, but these are not shown because no differences in structure
were observed, probably because the presence or absence of sucrose and the use of a different oil
had a small influence on the viscosity and hence on the emulsification process. In Figure 2a–d,
bacteria can be observed inside the water droplets. Figure 2a shows the W/O emulsion obtained when
emulsifying the bacterial suspension in the oil phase. Figure 2b shows the W/O/W emulsion obtained
after emulsifying the W/O emulsion in the outer aqueous phase. The suspension of antibubbles
obtained after freeze-drying the W/O/W of Figure 2b and reconstituting the subsequently obtained
antibubble powder in an aqueous phase is shown in Figure 2c,d. A clear difference is observed between
the droplets comprising oil (Figure 2b) and those in which the oil has been removed and replaced with
gas (Figure 2c). The replacement of oil with gas increases the scattering of light, and the antibubbles
are therefore darker than the double emulsion droplets. We used microscopic images to determine the
size distribution of the antibubbles and found a unimodal distribution with a number-averaged size of
83 ± 33 µm. Furthermore, it can be seen that the antibubbles have the same morphology as the double
emulsion droplets from which they originate, i.e., the freeze-drying process has little influence on the
morphology of the structures. It is important to note that the droplets of the bacterial suspension in
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Figure 2c are separated from the outer aqueous phase by a gas phase. There is no aqueous connection
between these inner droplets and the outer phase, as this would lead to an almost instantaneous
coalescence of the droplets with the outer phase, as was shown in previous work [11]. Inside the inner
droplets, a Brownian motion of the bacteria could be observed. This leads us to believe that the inner
droplets are in fact droplets, i.e., they are liquid. We expect that during reconstitution of the antibubble
powder the dry cores inside the antibubbles quickly rehydrate, since water vapor can pass through the
gas shell, and that this makes the cores liquid again.
Figure 2. Optical micrographs of the structure and stepwise production of the antibubbles using decane
and 10% maltodextrin + 8% sucrose. (a) Pickering-stabilized W/O emulsion; (b) Pickering-stabilized
W/O/W emulsion; (c) Antibubbles generated after freeze-drying the W/O/W emulsion and reconstituting
the resulting material; (d) as (c) but with a higher magnification; (e) Antibubbles after the addition of
bile salt. Scale bar represents 25 µm (panel d) or 50 µm (other panels).
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3.2. Survival of L. casei after Freeze-Drying and after Encapsulation inside Antibubbles
The survival of L. casei after encapsulation was significantly different (p-value < 0.001) for DM
antibubbles (6.5 ± 2.6% survival) and DMS antibubbles (29.8 ± 2.1%), as shown in Figure 3. On the
other hand, when cyclohexane was used as the oil phase, no viable bacteria were found in the resulting
antibubbles. This can be explained by the fact that decane has an octanol-water partitioning coefficient
log P = 5.6, whereas for cyclohexane, log P = 3.4. Solvents with a log P > 5 are considered relatively
nontoxic to bacteria [17]. For comparison, we also determined the survival of unencapsulated bacteria
during freeze-drying. The survival of the freeze-dried unencapsulated bacteria resuspended in 10%
maltodextrin or 10% maltodextrin + 8% sucrose was 20.2 ± 6.9% and 41.2 ± 14.4% (difference not
significant), respectively (Figure 3). Encapsulation thus led to a survival that was 13.7 and 11.4%
lower for the formulations with maltodextrin (significant difference with p = 0.02) and maltodextrin +
sucrose (difference not significant), respectively, than when the bacteria were not encapsulated but only
freeze-dried. The decreased survival can be explained in view of the fact that, during the encapsulation
process during the formation of the W/O emulsion, (part of) the bacteria come in contact with the
oil, which might interfere with the bacterial cell membrane integrity when combined with the high
shear forces in the emulsification process using a Turrax mixer [18]. Even though decane is relatively
nontoxic, this may still decrease the survival somewhat. Although encapsulation lowered the survival
when compared to freeze-drying alone, this decrease in survival was considerably smaller than the
decrease in survival resulting from freeze-drying.
Figure 3. Survival of bacteria after processing. Processing consists of encapsulation (formulations
CM, CMS, DM, DMS) or only freeze-drying (other two formulations). Values shown are means ±
standards deviations.
It is well-known that, in general, only part of the bacteria survives freeze-drying. The survival
degree that we observed after freeze-drying was comparable to the survival found in the literature for
the same strain [19,20]. The removal of both unbound and bound (hydrogen-bonded) water can occur
during freeze-drying and cause damage to bacteria [19]. Applying proteins and sugars as an additive
can counteract these negative effects. Previously, Miao et al. (2008) reported that disaccharides replace
the hydrogen bonds through interactions with the polar sites of the cell membrane and cellular proteins,
stabilizing their physical state and structures [21]. This can explain why, in our work, a mixture of
maltodextrin and sucrose resulted in a higher recovery of bacteria, both after encapsulation and after
freeze-drying alone, than when using only maltodextrin.
In literature reports, other encapsulation technologies also showed a reduction in the viability
of the bacteria. L. plantarum showed a 37% and 16% survival during encapsulation within a skim
milk-inulin-sodium alginate and an inulin-sodium alginate matrix, respectively [22]. Yao et al. (2018)
showed that the microgel preparation procedure for the encapsulation of Pediococcus pentosaceus Li05
reduced the cell viability to 22% [3]. The survival of bacteria found in these studies is comparable
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with the survival of bacteria found for the antibubble encapsulation process described in this paper.
This indicates that antibubble encapsulation is a good alternative technology in terms of the survival
of bacteria during the encapsulation process.
The entrapment efficiency was measured for the antibubble variant DMS and was found to be
88.7 ± 2.8%. This means that the great majority of the bacteria in this formulation are actually entrapped
within the antibubbles.
3.3. Survival of Unencapsulated Versus Encapsulated L. casei at Low pH
An important factor in the application of probiotics is their survival at a low pH. The survival of
bacteria at a low pH is limited because of the energy that the bacteria need to spend to maintain a neutral
intracellular pH, thus preventing vital metabolic reactions from taking place [23]. However, probiotics
should resist the stressful conditions of the stomach to be able to exert beneficial effects. Therefore, one of
the most important goals of encapsulation is to enhance the low pH tolerance of probiotics. The pH of
gastric juices is about 1.5–3 [24]. To determine the protective effect of antibubbles for L. casei against
acidic gastric conditions, the survival of unencapsulated versus encapsulated bacteria after 60 min
at pH 2 was investigated. This time was taken as an indication of the in vivo residence time in the
stomach. As encapsulated formulations, only the formulations DM and DMS were included, since the
formulations CM and CMS were found (Section 3.2) to contain a very low number of living bacteria.
An analysis by microscopy of the antibubbles did not show severe damage to the antibubbles at the end
of the low pH incubation period (date not shown). Significant differences were found in the survival of
unencapsulated bacteria and encapsulated bacteria. The survival of the bacteria after exposure to a low
pH was 31.6 ± 11.6% (0.5 log reduction) and 20.4 ± 4.9% (0.7 log reduction) of the initial population
found in the DM and DMS antibubbles (difference not significant), respectively (Figure 4). In contrast,
there was a huge loss of unencapsulated bacteria at pH 2. Only 3.0 ± 2.0% (1.5 log reduction) and
0.6 ± 0.6% (2.2 log reduction) of unencapsulated bacteria suspended in 10% maltodextrin and 10%
maltodextrin + 8% sucrose, respectively, survived exposure to pH 2 solutions. Sanchez et al. (2017)
reported a continuous decrease in viable bacteria, reaching 0 CFU/g for unencapsulated Lactobacillus
bacteria after 60 min in an acidic environment [25]. This is in agreement with our survival results for
unencapsulated bacteria.
Figure 4. Survival of unencapsulated and encapsulated bacteria after 1 h at pH 2. Values shown are
means ± standards deviations. Note that the encapsulated formulations indicated with ‘Maltodextrin’
and ‘Maltodextrin + Sucrose’ are also referred to as DM and DMS, respectively.
Our results show that antibubbles protect bacteria against exposure to low pH for at least one
hour. The difference in survival between encapsulated and unencapsulated bacteria is significant,
both for the formulations with only maltodextrin (p = 0.03) and for the formulations with maltodextrin
and sucrose (p = 0.02). However, even for the encapsulated bacteria, the observed survival is lower
than 100%. To better understand the protective effect of the gas shell against low pH, we performed a
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separate experiment in which we determined the survival of bacteria after 1 h in a 10% maltodextrin
solution, i.e., the inner water phase encapsulated inside the antibubbles. This survival was found to be
43.6%. This survival is within the range of the 31.6 ± 11.6% survival found for bacteria in maltodextrin
solution encapsulated within antibubbles. This suggests that the fact that the survival at a low pH is
lower than 100% is not the result of the low pH of the solution in which the antibubbles are dispersed
but rather an effect of an incomplete survival of the bacteria in the inner water phase. In the future,
in order to further enhance survival, the composition of the inner water phase could be optimized to
better sustain the viability of the encapsulated bacteria.
It is worth comparing the protective effect against a low pH that we found for antibubbles with
the protective effect of other encapsulation methods. Heidebach et al. (2009) encapsulated Lactobacilli
in hydrogel beads made of crosslinked caseinate with a size of around 200 micron and observed a
survival of less than 1% after one hour at pH 2.5 at 37 ◦C [26]. Chandramouli et al. (2004) encapsulated
Lactobacilli in 200-micron alginate beads and found that 1% survived after one hour at pH 2 at 37 ◦C [27].
Mandal et al. (2006) found that less than 5% of L. casei encapsulated in mm-sized alginate beads
survived after a one-hour incubation at pH 1.5 at 37 ◦C [28]. Although more work needs to be done,
e.g., incubation tests at 37 ◦C, we believe that the protective effect of antibubbles against a low pH
reported here is also promising when compared with the results obtained using conventional methods
such as encapsulation inside hydrogel beads.
Finally, we observed that adding a relevant concentration of bile salt to an antibubble suspension
quickly led to the coalescence of the inner water droplets contained by the antibubbles with the aqueous
phase that surrounded the antibubbles, i.e., the cores of the antibubbles were released: comparing
Figure 2e (after adding bile) with Figure 2c showed that the droplets of the inner water phase
(that contained the bacteria) present inside the bubbles in Figure 2c had disappeared. This is attributed
to the fact that bile salt is a surfactant that changes the wetting conditions of the hydrophobized fumed
silica, leading to the destabilization of the air shell and concomitant release of the inner droplets. Such a
release, triggered by a change in wetting conditions, has previously been described by Poortinga
(2013) [11] and Yohe et al. (2012) [29]. Further steps should be taken to more closely mimic the in vivo
situation, e.g., by adding gastric and intestinal enzymes and performing the incubation at 37 ◦C.
However, we feel that our finding that probiotic bacteria were released in the presence of a relevant
concentration of bile salt is a clear indication that antibubble-encapsulated probiotics will be released
along the intestinal tract, which is crucial for the probiotics to be functional.
4. Conclusions and Outlook
We have shown that L. casei can be encapsulated by Pickering-stabilized antibubbles. The survival
of L. casei during the encapsulation process was comparable to the survival of L. casei during
freeze-drying, provided that decane was used as the volatile oil during the encapsulation process.
Notably, encapsulation within antibubbles improved the viability of the bacteria after a 1 h incubation
at a low pH, demonstrating that this encapsulation approach may find application, e.g., to increase
the survival of probiotic bacteria along the digestive tract or to maintain the viability of probiotic
bacteria in acidic foods. We also observed that bile salts triggered the release of the encapsulated
bacteria, i.e., it is to be expected that bacteria will be released in the intestines, and in this way they
can induce their health benefits. To prove this, incubation tests need to be done under conditions that
more closely resemble in vivo conditions. Since bile salt can also decrease the viability of probiotics,
a further improvement would be to produce antibubble-encapsulated probiotics that are released
only in the large intestines. Additionally, it would be interesting to test the protective effect against
low pH for incubation times lasting weeks, which would be representative of food uses like acidic
dairy products or fruit juices. The stability of the antibubble powder obtained after freeze-drying has
not yet been consistently tested in our current work, but since probiotics are generally supplied in a
freeze-dried form, this stability is expected to be sufficient. The antibubbles consisted of maltodextrin,
hydrophobized silica and gas (air), and were produced using a volatile oil (in our case decane) as a
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processing aid, i.e., the oil is used during production but is then removed, so that the final product
should be nearly free of the oil. Maltodextrin is a common ingredient in food and pharmaceutical
products. The used hydrophobized silica is allowed for use in oral pharmaceuticals. The use of alkanes
in the production of oral pharmaceutical products is allowed, provided that the residual amount
of alkanes is below the limits given by the European Pharmacopeia. Therefore, we expect that the
antibubbles described here may be used in the formulation of pharmaceutical probiotic products.
To allow use in food, it may help to replace the hydrophobized silica with hydrophobic particles that are
more commonly used in food. This should be feasible based on the work already done on food-grade
Pickering stabilization [30]. Furthermore, although trace amounts of decane are naturally present in
foods like oregano and licorice, further investigations should be conducted on which volatile oil can
best be used as a processing aid to produce a food-grade formulation. In conclusion, we believe that,
although more work is still needed before a practical implementation is possible, we have presented a
potentially very versatile new method for the encapsulation of probiotics.
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